Creo Medical’s latest trading update delivers exactly what growth investors want to see: accelerating commercial momentum, surgical cost control, and a fortress balance sheet. Let’s dissect why this H1’25 report has the hallmarks of a company hitting its stride.
Core Growth Engine Firing on All Cylinders
That 40% jump in Core Technology revenue (£2.2m vs H1’24’s £1.6m) isn’t just a vanity metric. It signals:
- Commercial Validation: Hospitals aren’t just trialling Creo’s tech – they’re adopting it.
- Guidance Confidence: Management’s reiteration of 40-60% full-year growth, with the typical H2 weighting, suggests strong visibility.
- US Tailwinds Materialising: Those critical new CPT reimbursement codes for GI procedures are starting to do their job, directly benefiting Speedboat® devices.
The Cash Transformation: From Tightrope to War Chest
Let’s talk about the elephant in the room – that staggering cash position. Jumping from £8.7m at end-2024 to £20.5m just six months later is transformative. This wasn’t luck; it was strategy:
- CME Divestment Masterstroke: Selling 51% of Creo Medical Europe unlocked a €36m investment asset (recognised in H1) and provides future dividend income, while freeing Creo to focus on its core IP. Crucially, it removed a major cash drain.
- Relentless Cost Discipline: Underlying operating costs slashed to £9.1m (from £12.8m) showcase management’s grip on the burn rate. The £6.9m operating loss reduction is equally impressive.
- Streamlining Assets: The planned £1.75m sale of part of the Chepstow site is another smart, non-dilutive cash generator.
This cash runway isn’t just about survival; it’s about aggression. It funds commercial expansion, R&D, and potentially strategic moves.
Regulatory & Clinical Catalysts: Building Momentum
Creo isn’t resting on its GI laurels:
- SpydrBlade™ Flex FDA Clearance: Landing this in June expands their US GI toolkit, offering clinicians more flexibility right as reimbursement improves.
- MicroBlate™ Flex Gaining Traction: Commercial sales have started for lung tumour ablation, with more sites coming online. The initiation of the “ablate and resect” study at prestigious EU centres (Amsterdam UMC, Royal Brompton) is a vital step towards broader clinical adoption and evidence generation.
- Growing Clinical Evidence: The expanding library of papers and case studies using Creo devices is the quiet, essential work building long-term credibility with clinicians globally.
Partnership Power: The Micro-Tech Angle
The CME deal wasn’t just an exit; it was an entry into a powerful partnership. Reports of CME trading “above management expectations” are encouraging for Creo’s 49% stake and future dividends. More intriguingly, the active exploration of “strategic growth opportunities” together suggests potential synergies beyond Europe – perhaps leveraging Micro-Tech’s extensive distribution?
Outlook: Confidence Rooted in Execution
The Board’s confidence feels well-founded. They’ve delivered on:
- Revenue Growth: Hitting the H1 target.
- Cost Reduction: Significant savings achieved.
- Cash Generation: Balance sheet radically strengthened.
- Pipeline Progress: New products cleared, new indications advancing.
The path towards self-sustaining cashflows looks clearer than ever.
The October Capital Markets Event: One to Watch
Mark Thursday 9th October in the diary. Hosted at Deutsche Numis, this event is likely where Creo will unveil more granular details on:
- US commercial rollout post-CPT codes.
- MicroBlate™ Flex progress in lung.
- The evolving strategy with Micro-Tech.
- Updated financial trajectory towards breakeven.
Expect significant investor interest.
Final Thoughts: From Turnaround Story to Growth Story?
Creo’s H1 update is a compelling narrative of a company executing a difficult pivot. They’ve shed non-core burdens, tightened operations, secured crucial regulatory wins, and crucially, demonstrated their core technology can drive significant revenue growth. The leap in cash reserves provides vital breathing room and strategic optionality. While the journey to profitability continues, the pieces are falling into place with much greater certainty. The market will now be looking for H2 to deliver the expected acceleration and for the Capital Markets Event to provide the next chapter in what’s becoming a much more convincing growth story.
